Lila capturing venture upside through spinouts

This points to Lila trying to capture venture style upside, not just lab fees. In Creation, the company is not only running experiments for a customer, it is packaging the output into something that can live on as a licensable asset, a dedicated product line, or a standalone startup. That matters because successful programs can turn one discovery campaign into long lived IP economics, including milestones, royalties, or equity.1 2 3

• Creation sits above ordinary lab services. Instead of charging only for instrument time or model access, Lila delivers validated molecules, materials, protocols, and data packages, then can keep participating economically if that package becomes a business.1 2
• This is a familiar commercialization pattern in biotech incubation. Lila was formed within Flagship Pioneering, which has a long history of turning technical platforms into new venture backed companies, so company formation is a built in path for monetizing strong internal discoveries.3 4
• The model also fits Lila's cost base. Running AI Science Factories and frontier models is expensive, so asset level upside helps justify the heavy fixed investment in labs by giving Lila a shot at returns much larger than a normal services contract.1 2

Going forward, the highest value outcome for Lila is likely a portfolio model where Catalyst fills the factories and Creation spins out the best results into proprietary assets and occasional new companies. If that works, Lila starts to look less like a contract research provider and more like a discovery engine with its own balance sheet upside.1 2 3